Pfizer\'s Talzenna approved in Europe for HER2 advanced breast cancer with gBRCA12 mutations httpbit.ly2RtJR6e pharmapic.twitter.comyIHJqR9u9S

Pfizer's Talzenna approved in Europe for HER2- advanced breast cancer with gBRCA1/2 mutations http://bit.ly/2RtJR6e  #pharmapic.twitter.com/yIHJqR9u9S

07:45 EDT 24 Jun 2019 | Pharmafile

Pfizer's Talzenna approved in Europe for HER2- advanced breast cancer with gBRCA1/2 mutations http://bit.ly/2RtJR6e  #pharma pic.twitter.com/yIHJqR9u9S

More From BioPortfolio on "Pfizer's Talzenna approved in Europe for HER2- advanced breast cancer with gBRCA1/2 mutations http://bit.ly/2RtJR6e  #pharmapic.twitter.com/yIHJqR9u9S"